Unknown

Dataset Information

0

Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.


ABSTRACT: Downstaging (DS) of rectal cancers is achieved in approximately 45% of patients with neoadjuvant fluorouracil (FU) -based chemoradiotherapy (CRT). Polymorphisms in the thymidylate synthase gene (TYMS) had previously defined two risk groups associated with disparate tumor DS rates (60% v 22%). We conducted a prospective single-institution phase II study using TYMS genotyping to direct neoadjuvant CRT for patients with rectal cancer.Patients with T3/T4, N0-2, M0-1 rectal adenocarcinoma were evaluated for germline TYMS genotyping. Patients with TYMS *2/*2, *2/*3, or *2/*4 (good risk) were treated with standard chemoradiotherapy using infusional FU at 225 mg/m²/d. Patients with TYMS *3/*3 or *3/*4 (poor risk) were treated with FU/RT plus weekly intravenous irinotecan at 50 mg/m². The primary end point was pathologic DS. Secondary end points included complete tumor response (ypT0), toxicity, recurrence rates, and overall survival.Overall, 135 patients were enrolled, of whom 27.4% (37 of 135) were considered poor risk. The prespecified statistical goals were achieved, with DS and ypT0 rates reaching 64.4% and 20% for good-risk and 64.5% and 42% for poor-risk patients, respectively.To our knowledge, this is the first study to prospectively use TYMS genotyping to direct neoadjuvant CRT in patients with rectal cancer. High rates of DS and ypT0 were achieved among both risk groups when personalized treatment was based on TYMS genotype. These results are encouraging, and further evaluation of this genotype-based strategy using a randomized study design for locally advanced rectal cancer is warranted.

SUBMITTER: Tan BR 

PROVIDER: S-EPMC3068061 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.

Tan Benjamin R BR   Thomas Fabienne F   Myerson Robert J RJ   Zehnbauer Barbara B   Trinkaus Kathryn K   Malyapa Robert S RS   Mutch Matthew G MG   Abbey Elliot E EE   Alyasiry Amer A   Fleshman James W JW   McLeod Howard L HL  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110104 7


<h4>Purpose</h4>Downstaging (DS) of rectal cancers is achieved in approximately 45% of patients with neoadjuvant fluorouracil (FU) -based chemoradiotherapy (CRT). Polymorphisms in the thymidylate synthase gene (TYMS) had previously defined two risk groups associated with disparate tumor DS rates (60% v 22%). We conducted a prospective single-institution phase II study using TYMS genotyping to direct neoadjuvant CRT for patients with rectal cancer.<h4>Patients and methods</h4>Patients with T3/T4,  ...[more]

Similar Datasets

| S-EPMC4169411 | biostudies-literature
2015-10-01 | GSE60646 | GEO
| S-EPMC5584556 | biostudies-literature
| S-EPMC6890979 | biostudies-literature
| S-EPMC4650974 | biostudies-literature
| S-EPMC7334091 | biostudies-literature
| S-EPMC3104075 | biostudies-literature
| S-EPMC8545722 | biostudies-literature
| S-EPMC6744983 | biostudies-literature
| S-EPMC9362876 | biostudies-literature